This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Dessel, H. J. H. M. T. Articles by Giudice, L. C. Search for Related Content PubMed PubMed Citation Articles by van Dessel, H. J. H. M. T. Articles by Giudice, L. C.

Elevated Serum Levels of Free Insulin-Like Growth Factor I in Polycystic Ovary Syndrome¹

Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Erasmus University Medical Center (H.J.H.M.T.v.D., B.C.J.M.F.), 3015 GD Rotterdam, The Netherlands; the Department of Pediatrics, Baylor College of Medicine (P.D.K.L.), Houston, Texas 77030; and the Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology and Infertility, Stanford University Medical Center (G.F., L.C.G.), Stanford, California 94305-5317

Address all correspondence and requests for reprints to: Linda C. Giudice, M.D., Ph.D., Department of Gynecology and Obstetrics, Division of Reproductive Endocrinology, Stanford University Medical Center, Stanford, California 94305. E-mail: giudice{at}stanford.edu

Polycystic ovary syndrome (PCOS) is the most common cause of anovulation in women. Previous studies suggest that the pathogenesis of PCOS may involve interrelated abnormalities of the insulin-like growth factor (IGF) and ovarian steroidogenesis systems. We investigated this hypothesis in fasting serum samples from 140 women with PCOS (age, 27.4 ± 0.4 yr; body mass index, 26.3 ± 0.5 kg/m²; mean ± SEM). IGF-related parameters were also studied in a group of normoovulatory women (n = 26; age, 26 ± 4 yr; body mass index, 23.6 ± 4.3 kg/m²). For the PCOS group, the mean testosterone (T) level was 2.5 ± 0.1 nmol/L, and it was significantly correlated with LH (r = 0.41; P < 10^-6), estrone (r = 0.33; P = 0.016), estradiol (r = 0.18; P = 0.04), and androstenedione (AD; P < 10^-6), but not with dehydroepiandrosterone sulfate (P = 0.71), a marker of adrenal steroidogenesis. T and AD were also related to total ovarian follicle number and ovarian size, as previously found with normoovulatory women (1). There were no differences between the PCOS subjects and the normoovulatory group for total IGF-I, IGF-II, or IGF-binding protein-3 (IGFBP-3). However, IGFBP-1 levels were significantly decreased in the PCOS group (1.0 ± 0.2 vs. 7.3 ± 1.1 ng/mL; P < 0.001) and were inversely correlated with serum insulin levels (r = -0.50; P < 10^-8). Serum levels of free IGF-I (fIGF-I) were elevated (5.9 ± 0.3 vs. 2.7 ± 0.3 ng/mL; P < 0.001) in inverse relation with IGFBP-1 (r = -0.31; P = 0.046). Serum fIGF-I levels were related to total follicle number (r = -0.35; P < 10^-4) and to the ratio of sex hormone-binding globulin to T (r = -0.23; P = 0.009). However, these relationships were not independent of other variables. Despite the more than 2-fold elevation in fIGF-I levels, significant relationships between fIGF-I and markers of ovarian steroidogenesis (T, AD, estradiol, and estrone) could not be demonstrated.

In conclusion, although we confirmed correlations between LH and hyperandrogenemia and have found abnormalities in the IGF system in a large cohort of PCOS subjects, a direct relationship between hyperandrogenism and the IGF system could not be shown. Previous studies suggest that elevated LH and hyperinsulinemia lead to excess ovarian androgen synthesis in PCOS and that the intraovarian IGF system is important for normal follicle development and may be important in the arrested state of follicle development in PCOS. However, the data presented in this cross-sectional study suggest that insulin-related changes in circulating IGFBP-1 and subsequent elevation of fIGF-I reflect insulin resistance and have little enhancing effects on ovarian steroidogenesis in this disorder.

This article has been cited by other articles:

				E. Louden, M. M Chi, and K. H Moley Crosstalk between the AMP-activated kinase and insulin signaling pathways rescues murine blastocyst cells from insulin resistance Reproduction, September 1, 2008; 136(3): 335 - 344. [Abstract] [Full Text] [PDF]

				D. S. Wachs, M. S. Coffler, P. J. Malcom, and R. J. Chang Comparison of Follicle-Stimulating-Hormone-Stimulated Dimeric Inhibin and Estradiol Responses as Indicators of Granulosa Cell Function in Polycystic Ovary Syndrome and Normal Women J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2920 - 2925. [Abstract] [Full Text] [PDF]

				N. A. Cataldo, F. Abbasi, T. L. McLaughlin, M. Basina, P. Y. Fechner, L. C. Giudice, and G. M. Reaven Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome Hum. Reprod., January 1, 2006; 21(1): 109 - 120. [Abstract] [Full Text] [PDF]

				D. Glintborg, R. K. Stoving, C. Hagen, A. P. Hermann, J. Frystyk, J. D. Veldhuis, A. Flyvbjerg, and M. Andersen Pioglitazone Treatment Increases Spontaneous Growth Hormone (GH) Secretion and Stimulated GH Levels in Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5605 - 5612. [Abstract] [Full Text] [PDF]

				J. A.M. de Boer, C. B. Lambalk, H. H. Hendriks, C. van Aken, E. A. van der Veen, and J. Schoemaker Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 504 - 509. [Abstract] [Full Text] [PDF]

				J. S. E. Laven, A. G. M. G. J. Mulders, J. A. Visser, A. P. Themmen, F. H. de Jong, and B. C. J. M. Fauser Anti-Mullerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive Age J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 318 - 323. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				M. E. Silfen, M. R. Denburg, A. M. Manibo, R. A. Lobo, R. Jaffe, M. Ferin, L. S. Levine, and S. E. Oberfield Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4682 - 4688. [Abstract] [Full Text] [PDF]

				M. R. Denburg, M. E. Silfen, A. M. Manibo, D. Chin, L. S. Levine, M. Ferin, D. J. McMahon, C. Go, and S. E. Oberfield Insulin Sensitivity and the Insulin-Like Growth Factor System in Prepubertal Boys with Premature Adrenarche J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5604 - 5609. [Abstract] [Full Text] [PDF]

				L. Cordain, S. Lindeberg, M. Hurtado, K. Hill, S. B. Eaton, and J. Brand-Miller Acne Vulgaris: A Disease of Western Civilization Arch Dermatol, December 1, 2002; 138(12): 1584 - 1590. [Abstract] [Full Text] [PDF]

				M. E. Silfen, C. H. L. Shackleton, A. M. Manibo, L. S. Levine, D. Sekhar, D. J. McMahon, and S. E. Oberfield 5{alpha}-Reductase and 11{beta}-Hydroxysteroid Dehydrogenase Activity in Prepubertal Hispanic Girls with Premature Adrenarche J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4647 - 4651. [Abstract] [Full Text] [PDF]

				B. O. Yildiz, I. C. Haznedaroglu, S. Kirazli, and M. Bayraktar Global Fibrinolytic Capacity Is Decreased in Polycystic Ovary Syndrome, Suggesting a Prothrombotic State J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3871 - 3875. [Abstract] [Full Text] [PDF]

				M. E. Silfen, A. M. Manibo, M. Ferin, D. J. McMahon, L. S. Levine, and S. E. Oberfield Elevated Free IGF-I Levels in Prepubertal Hispanic Girls with Premature Adrenarche: Relationship with Hyperandrogenism and Insulin Sensitivity J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 398 - 403. [Abstract] [Full Text] [PDF]

				C. V. Obiezu, A. Scorilas, A. Magklara, M. H. Thornton, C. Y. Wang, F. Z. Stanczyk, and E. P. Diamandis Prostate-Specific Antigen and Human Glandular Kallikrein 2 Are Markedly Elevated in Urine of Patients with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1558 - 1561. [Abstract] [Full Text]

				V. De Leo, A. la Marca, G. Morgante, L. Ciotta, L. Mencaglia, A. Cianci, and F. Petraglia Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome Hum. Reprod., November 1, 2000; 15(11): 2302 - 2305. [Abstract] [Full Text] [PDF]

				J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3496 - 3506. [Full Text]

				B. Imani, M. J. C. Eijkemans, F. H. de Jong, N. N. Payne, P. Bouchard, L. C. Giudice, and B. C. J. M. Fauser Free Androgen Index and Leptin Are the Most Prominent Endocrine Predictors of Ovarian Response during Clomiphene Citrate Induction of Ovulation in Normogonadotropic Oligoamenorrheic Infertility J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 676 - 682. [Abstract] [Full Text]